ライフサイエンスコーパス: herpes simplex virus 2

1 ain STIs, including human papillomavirus and herpes simplex virus 2.

2 %; varicella zoster virus, 3%; HHV7, 2%; and herpes simplex virus 2, 1%.

3 1% vs. 1.2% without coinfection; P<.001) and herpes simplex virus 2 (2.7% vs. 1.0%; P=.003).

4 ted with human immunodeficiency virus (HIV), herpes simplex virus 2, and CMV starting antiretroviral

5 trachomatis, Treponema pallidum (syphilis), herpes simplex virus 2, and HIV.

6 eal a promising vaccination strategy against herpes simplex virus 2, and potentially against other se

7 on development in an intravaginal guinea pig herpes simplex virus-2 assay.

8 1 and other sexually transmitted infections (herpes simplex virus-2, bacteria, fungi), which reprogra

9 fect of coadministration of this drug with a herpes simplex virus-2-based oncolytic virus (FusOn-H2)

10 V is an alpha-herpesvirus closely related to herpes simplex virus 2, enabling prediction of the VZV g

11 Herpes simplex virus 2 (HSV-2) and, to a lesser extent,

12 viously established that cells infected with herpes simplex virus 2 (HSV-2) are disrupted in their ab

13 primary outcomes were prevalence of HIV and herpes simplex virus 2 (HSV-2) at 18 months and were ass

14 We constructed a herpes simplex virus 2 (HSV-2) bacterial artificial chro

15 o vaccine that is safe and effective against herpes simplex virus 2 (HSV-2) disease has been licensed

16 mpts to develop a vaccine to prevent genital herpes simplex virus 2 (HSV-2) disease have been only ma

17 haherpesviruses pseudorabies virus (PRV) and herpes simplex virus 2 (HSV-2) displays previously uncha

18 Subunit vaccines based on the herpes simplex virus 2 (HSV-2) glycoprotein D (gD-2) hav

19 The vaccine consisted of a soluble form of herpes simplex virus 2 (HSV-2) glycoprotein D (gD2) with

20 A recent phase 3 trial with soluble herpes simplex virus 2 (HSV-2) glycoprotein D (gD2t) in

21 A herpes simplex virus 2 (HSV-2) glycoprotein E deletion m

22 nital herpes prophylactic vaccine containing herpes simplex virus 2 (HSV-2) glycoproteins C (gC2) and

23 Several prophylactic vaccines targeting herpes simplex virus 2 (HSV-2) have failed in the clinic

24 y of medical male circumcision (MMC) against herpes simplex virus 2 (HSV-2) incidence among men in th

25 Herpes simplex virus 2 (HSV-2) infection causes signific

26 Patients with newly acquired genital herpes simplex virus 2 (HSV-2) infection have virus freq

27 iological studies have reported that genital herpes simplex virus 2 (HSV-2) infection increases the r

28 idemiological studies have demonstrated that herpes simplex virus 2 (HSV-2) infection significantly i

29 used a mouse model of vaginally-transmitted herpes simplex virus 2 (HSV-2) infection to test polymer

30 s required for full protection from a lethal herpes simplex virus 2 (HSV-2) infection.

31 Herpes simplex virus 2 (HSV-2) is a causative agent of g

32 Herpes simplex virus 2 (HSV-2) is a major global pathoge

33 Genital infection with herpes simplex virus 2 (HSV-2) is linked to an increased

34 While herpes simplex virus 2 (HSV-2) is the most common cause

35 Herpes simplex virus 2 (HSV-2) is the primary cause of g

36 phenotypes, we studied the expression of the herpes simplex virus 2 (HSV-2) LAT-associated microRNAs

37 ed viral microRNA (miRNA), miR-I, encoded by herpes simplex virus 2 (HSV-2) latency-associated transc

38 e applications, we compared a humanized anti-herpes simplex virus 2 (HSV-2) Mab expressed in mammalia

39 Herpes simplex virus 2 (HSV-2) may cause frequent recurr

40 Genital herpes can be caused by herpes simplex virus 2 (HSV-2) or, less commonly, by her

41 ified virion host shutoff protein (vhs) as a herpes simplex virus 2 (HSV-2) protein capable of disrup

42 Most herpes simplex virus 2 (HSV-2) reactivations in humans a

43 Herpes simplex virus 2 (HSV-2) strains containing mutati

44 Herpes simplex virus 2 (HSV-2) subunit antigen vaccines

45 Importance: Several herpes simplex virus 2 (HSV-2) subunit vaccine studies h

46 Immunotherapeutic herpes simplex virus 2 (HSV-2) vaccine efficacy depends

47 No herpes simplex virus 2 (HSV-2) vaccine has been licensed

48 The herpes simplex virus 2 (HSV-2) viral microRNA (miRNA) de

49 human sacral ganglia latently infected with herpes simplex virus 2 (HSV-2) was used to identify HSV-

50 potential by exploring its activity against herpes simplex virus 2 (HSV-2), a cofactor for HIV acqui

51 monocytes in primary mucosal infection with herpes simplex virus 2 (HSV-2), and demonstrate that mon

52 llions of people worldwide are infected with herpes simplex virus 2 (HSV-2), and to date, an efficaci

53 Herpes simplex virus 2 (HSV-2), the principal causative

54 aginal lumen susceptible to inoculation with herpes simplex virus 2 (HSV-2).

55 e utility of IL-12 cDNA as an adjuvant for a herpes simplex virus-2 (HSV-2) DNA vaccine in a mouse ch

56 The role of autophagy in Herpes simplex virus-2 (HSV-2) infection is unknown.

57 Herpes simplex virus-2 (HSV-2) is a chronic reactivating

58 Herpes simplex virus-2 (HSV-2) is periodically shed thro

59 Herpes simplex virus-2 (HSV-2) is shed episodically, lea

60 Herpes simplex virus-2 (HSV-2) shedding episodes in huma

61 s demonstrated by passive immunization using herpes simplex virus-2 (HSV-2)-specific polyclonal serum

62 in response to either live or UV-inactivated Herpes simplex virus-2 (HSV-2).

63 Herpes simplex virus 2 infection is characterized by cyc

64 ndom use, and, in HIV-1-uninfected partners, herpes simplex virus 2 infection, genital ulcers, Tricho

65 ll protocol reduces the spread of infectious herpes simplex virus 2 into the sensory neurons and prev

66 The recent crystal structures of gH/gL from herpes simplex virus 2, pseudorabies virus, and Epstein-

67 ne (H11) that codes for a protein similar to herpes simplex virus 2 ribonucleotide reductase protein

68 ected partners and by age, pregnancy status, herpes simplex virus 2 serostatus, and male circumcision

69 ed for immunization, we constructed a mutant herpes simplex virus 2 strain containing two deletion mu

70 peptides from a randomly chosen protein, the herpes simplex virus-2 tegument protein UL49, correlated

71 support for a relationship between prenatal herpes simplex virus 2 type exposure and risk of schizop

72 quence encoding the carboxyl terminus of the herpes simplex virus 2 UL27.5 sequence.